Processa Pharmaceuticals, Inc. (PCSA) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies. The company is currently conducting a Phase 2 clinical trial for its lead candidate, NGC-Cap, in advanced or metastatic breast cancer. The company has no product revenue and relies on equity financing to fund operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,377,179) | $(2,834,405) |
| Net Loss Per Share (Basic/Diluted) | $(1.29) | $(7.58) |
| Cash and Cash Equivalents (End of Period) | $1,691,043 | $2,897,072 |
| Net Cash Used in Operating Activities | $(3,590,695) | $(2,729,848) |
| Total Assets | $4,520,974 | $7,813,567 |
| Accumulated Deficit | $(104,160,212) | $(90,053,604) |
| Digital Assets (Fair Value) | $1,585,356 | $1,145,180 |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $543,000 (19%) compared to Q1 2025, driven by higher operating expenses.
- Expense Growth:
- R&D Expenses: Increased by $221,000 to $1.81 million, primarily due to higher professional fees for the Phase 2 clinical trial.
- G&A Expenses: Increased by $264,000 to $1.52 million, driven by higher professional fees, insurance, and travel costs.
- Cash Position: Cash and cash equivalents decreased by $3.85 million during the quarter. Total assets declined significantly due to the cash burn and a reduction in prepaid expenses.
- Digital Assets: The company purchased an additional $500,000 in Chiliz (CHZ) tokens during the quarter. Despite the purchase, the portfolio recorded an unrealized loss of $59,824.
- Capital Raise: The company raised approximately $245,000 in net proceeds from the issuance of common stock during Q1 2026, a significant decrease from the $4.4 million raised in Q1 2025.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for one year from the filing date. With only $1.7 million in cash at quarter-end (plus $219,000 raised in April 2026), the company expects to need additional capital in Q2 2026.
- Operational Focus: The company is focused on the interim analysis of the NGC-Cap Phase 2 trial, expected to be completed in the first half of 2026. No product revenue is expected in the foreseeable future.
- Legal Proceedings:
- Elion Dispute: Ongoing litigation regarding the termination of a license agreement. The company disputes the termination and is seeking damages.
- Investor Lawsuit: A lawsuit filed by former investors alleging fraud and negligent misrepresentation. While some counts were dismissed, the case remains active with discovery ongoing.
- Contractual Obligations: The company has contractual obligations of up to $11.2 million for future services with Contract Research Organizations (CROs), contingent on trial progress.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current cash ($1.7M) plus recent April raises ($219k) against the projected burn rate of ~$3.6M per quarter.
- Funding Timeline: Confirm the status of planned fundraising efforts for Q2 2026 to avoid operational suspension.
- Legal Exposure: Monitor the status of the Elion license dispute and the investor fraud lawsuit for potential material adverse judgments.
- Clinical Milestones: Track the completion and results of the NGC-Cap Phase 2 interim analysis expected in H1 2026.
- Digital Asset Volatility: Assess the impact of Chiliz (CHZ) token price fluctuations on the balance sheet and potential unrealized losses.